Alamar Biosciences is a privately held life sciences company with a mission to transform the field of proteomics to enable the early detection of cancer and other diseases. The company's two proprietary technology platforms, NULISA™ and Attobody™, work seamlessly with the latest advances in genomics to achieve single-digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. The Attobodies have picomolar affinity and built-in high specificity and have the potential to expand antibody therapeutics to many targets intractable with conventional antibodies.
